2022年

≪英文≫

STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma.

Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, Omura T, Ikemi Y, Nakagawa S, Yonezawa A, Ogawa O, Matsubara K, Iwamoto T, Nishikawa K, Hayashi S, Tohara D, Murakami Y, Motoshima T, Joho H, Yano I.

Oncol Res. 2022 Jan 11. doi: 10.3727/096504022X16418911579334. Online ahead of print. PMID: 35016744

 

Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Abe H, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group.

(Kurahashi R is indicated in Acknowledgement.)

J Geriatr Oncol. 2022;13(1):88-93.

 

≪和文≫